ArticleAntimicrobial agents and chemotherapy2018
Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam.
Open access · bronzeAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- Development of a novel LC-MS/MS method for concurrent determination of imipenem, relebactam, and cilastatin in human serum, urine and peritoneal drainage fluid.BMC chemistry · 2026Article
- New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Lung Transplantation: Clinical Evidence, Safety, and PK/PD Properties.Transplant international : official journal of the European Society for Organ Transplantation · 2026Review
- Article
- Crystal structure of the class A extended-spectrum β-lactamase CTX-M-96 in complex with relebactam at 1.03 Angstrom resolution.Antimicrobial agents and chemotherapy · 2024Article
- New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Liver Transplantation: Clinical Perspectives, Toxicity, and PK/PD Properties.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review.Microorganisms · 2023Review
- Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review.Drugs · 2023Review
- Susceptibility profile and β-lactamase content of globalJAC-antimicrobial resistance · 2023Article
- New antibiotics for Gram-negative pneumonia.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Antibiogram at a Rural Hospital Against the Background of COVID-19: A Five-Year Retrospective Review.Cureus · 2022Article
- Molecular Mechanism of the β-Lactamase Mediated β-Lactam Antibiotic Resistance ofFrontiers in microbiology · 2022Article
- Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli.Antimicrobial agents and chemotherapy · 2021Article
- Cefiderocol Activity Against ClinicalOpen forum infectious diseases · 2021Article
- Review
- The Building Blocks of Antimicrobial Resistance inFrontiers in cellular and infection microbiology · 2021Review
- New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams.International journal of molecular sciences · 2020Review
- Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".Infectious disease clinics of North America · 2020Review
- Clinical Pharmacokinetics and Pharmacodynamics of Imipenem-Cilastatin/Relebactam Combination Therapy.Clinical pharmacokinetics · 2020Review
- A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date.Infection and drug resistance · 2020Review
- The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.Expert opinion on pharmacotherapy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Melissa D BarnesResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
Christopher R BethelResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
Jim AlsopUniversity of Minnesota, Minneapolis, Minnesota, USA.
Scott A BeckaResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
Joseph D RutterResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
Krisztina M Papp-WallaceResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA krisztina.papp@va.gov robert.bonomo@va.gov.
Robert A BonomoResearch Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA krisztina.papp@va.gov robert.bonomo@va.gov.
Louis Stokes Cleveland VA Medical Center · USCase Western Reserve University · USUniversity of Minnesota · US
Funding
Therapeutics for drug resistant-bacteria: Arylpropionyl-phloroglucinolsU19AI109713 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI PERLIN, DAVID S · 2014 to 2018
$26.9MUnderstanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MMolecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniaeR21AI114508 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., VAN DUIN, DAVID · 2015 to 2016
$445kThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–Targeting Burkholderial β-lactamases: Structure, function, and regulationI01BX002872 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI DONSKEY, CURTIS, PAPP-WALLACE, KRISZTINA MARGARET · 2016 to 2023
–BLRD VA I01 BX001974BLRD VA I01 BX002872NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIAID NIH HHS R21 AI114508NIAID NIH HHS U19 AI109713
Abstract
PubMed holds no abstract for this paper.
Indexed as
Azabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-LactamasesCephalosporinaseCilastatinImipenemMicrobial Sensitivity TestsPseudomonasPseudomonas aeruginosaAzabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-LactamasesCephalosporinaseCilastatinImipenemrelebactamAmpCdiazabicyclooctane inhibitorimipenemPDC-3Pseudomonas aeruginosarelebactamβ-lactamβ-lactamase
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.